Belarus Pharmaceuticals and Healthcare Report Q2 2015

  • March 2015
  • -
  • Business Monitor International
  • -
  • 88 pages

Includes 3 FREE quarterly updates

BMI View:

The volatility of the Belarusian rouble and high inflation will hurt consumer incomes and therefore the growth outlook of the pharmaceutical market over the next two years. Furthermore, increased scrutiny by President Lukashenko over pharmaceutical imports indicates that Belarus may follow neighbouring Russia in instituting measures that favour the domestic industry and restrict the market for pharmaceutical imports.

Headline Expenditure Projections

Pharmaceuticals: BYR10,223bn in 2014 (USD998mn) to BYR12,101bn (USD869mn) in 2015; +18.4% in local currency terms and -12.9% in US dollar terms.
Healthcare: BYR36,100bn (USD3.50bn) in 2013 to BYR42,419bn (USD3.05bn) in 2015; +17.5% in local currency terms and -13.5% in US dollar terms.

Table Of Contents

Belarus Pharmaceuticals and Healthcare Report Q2 2015
BMI Industry View 7
SWOT 9
Political 11
Economic 12
Industry Forecast 13
Pharmaceutical Market Forecast 13
Table: Pharmaceutical Sales, Historical Data And Forecasts (Belarus 2011-2019) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2011-2019) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2011-2019) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2011-2019) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Belarus 2011-2019) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Belarus 2011-2019) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Belarus 2011-2019) 26
OTC Medicine Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Belarus 2011-2019) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Belarus 2011-2019) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Belarus 2011-2019) 32
Key Risks To BMI's Forecast Scenario 33
Macroeconomic Forecasts 34
Economic Analysis 34
Table: GDP Contribution To Growth (Belarus 2011-2019) 39
Industry Risk Reward Ratings 40
Central And Eastern Europe Risk/Reward Index 40
Belarus Risk/Reward Index 45
Rewards 46
Risks 46
Market Overview 48
Industry Trends And Developments 50
Epidemiology 50
Healthcare Sector 51
Healthcare Provision 52
Healthcare Sector Reforms 53
Healthcare Insurance 54
Table: Healthcare Resources 54
Table: Healthcare Activity 55
Table: Healthcare Personnel 55
Medical Tourism 56
Research And Development 56
Clinical Trials 57
Regulatory Development 58
Recent Regulatory Developments 58
Customs Union 59
Pharmaceutical Advertising 59
Intellectual Property Rights 60
Counterfeit Drugs 61
Pricing And Reimbursement 61
Recent Pricing and Reimbursement Developments 62
Tendering Procedures 63
Competitive Landscape 64
Pharmaceutical Sector 64
Generic Drugmakers 65
Research-Based Industry 67
Recent Pharmaceutical Sector Developments 68
Pharmaceutical Wholesale And Retail 68
Company Profile 70
Belbiopharm 70
Lekpharm 75
Demographic Forecast 77
Demographic Outlook 77
Table: Population Headline Indicators (Belarus 1990-2025) 78
Table: Key Population Ratios (Belarus 1990-2025) 78
Table: Urban/Rural Population and Life Expectancy (Belarus 1990-2025) 79
Table: Population By Age Group (Belarus 1990-2025) 79
Table: Population By Age Group % (Belarus 1990-2025) 80
Glossary 82
Methodology 84
Pharmaceutical Expenditure Forecast Model 84
Healthcare Expenditure Forecast Model 84
Notes On Methodology 85
Risk/Reward Index Methodology 86
Index Overview 87
Table: Pharmaceutical Risk/Reward Index Indicators 87
Indicator Weightings 88

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with ...

OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • January 2015
  • by Global Data

OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018 Summary GlobalData estimates that the 2013 sales for the Cushing’s syndrome (CS) therapeutic market was approximately ...

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.